Retraction notice to “Sun exposure related methylation in malignant and non-malignant skin lesions” [Cancer Letters 245/1-2 (2007) 112-120] (S0304383506000036) (10.1016/j.canlet.2005.12.042));Sun exposure related methylation in malignant and non-malignant skin lesions

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 112-120

  Sathyanarayana, Ubaradka G ^a,b   Moore, Angela Yen ^c,d,e   Li, Lin ^f   Padar, Asha ^a   Majmudar, Kuntal ^a   Stastny, Victor ^a   Makarla, Prakash ^b   Suzuki, Makoto ^a   Minna, John D ^a,b   Feng, Ziding ^f   Gazdar, Adi F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Arlington Center for Dermatology   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cadherins; Laminin 5; Methylation; MSP; Skin cancer

Indexed keywords

CADHERIN; CLAUDIN 7; CYCLIN D2; GENE PRODUCT; H CADHERIN; KALININ; LAMININ A3; LAMININ B3; LAMININ C2; P CADHERIN; PROTEIN BETAIG H3; PROTEIN P16INK4A; PROTEIN PRECURSOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TIGHT JUNCTION PROTEIN 2A; UVOMORULIN;

ARTICLE; BASAL CELL CARCINOMA; BETAIG H3 GENE; CCND2 GENE; CDH1 GENE; CDH13 GENE; CDH3 GENE; CLDN7 GENE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAMA3 GENE; LAMB3 GENE; LAMC2 GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; P16INK4A GENE; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; RASSF1A GENE; REAL TIME POLYMERASE CHAIN REACTION; SKIN CANCER; SKIN PROTECTION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TJP2A GENE; TUMOR SUPPRESSOR GENE;

EID: 33845652565     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.07.010     Document Type: Erratum

References (40)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Backvall H., Wolf O., Hermelin H., Weitzberg E., and Ponten F. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br. J. Dermatol. 150 (2004) 259-266
3. Melnikova V.O., and Ananthaswamy H.N. Cellular and molecular events leading to the development of skin cancer. Mutat. Res. 571 (2005) 91-106
4. Safai B. In: Devita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Priniciples and Practice of Oncology. fifth ed. (1977), Lippincott/Raven Press, Philadelphia, PA 1883-1933
5. Green C.L., and Khavari P.A. Targets for molecular therapy of skin cancer. Semin. Cancer Biol. 14 (2004) 63-69
6. Shapiro G.I., Park J.E., Edwards C.D., Mao L., Merlo A., Sidransky D., et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55 (1995) 6200-6209
7. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., and Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72 (1998) 141-196
8. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24 (2000) 132-138
9. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002) 5427-5440
10. Brown V.L., Harwood C.A., Crook T., Cronin J.G., Kelsell D.P., and Proby C.M. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J. Invest. Dermatol. 122 (2004) 1284-1292
11. Chiles M.C., Ai L., Zuo C., Fan C.Y., and Smoller B.R. E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod. Pathol. 16 (2003) 1014-1018
12. Carcinoma of the Skin (Excluding Eyelid, Vulva, and Penis), in: Anonymous, American Joint Committee on Cancer: AJCC Cancer Staging Manual, sixth ed., Springer, New York, 2002, pp. 203-208.
13. Herrmann B.G., and Frischauf A.M. Isolation of genomic DNA. Methods Enzymol. 152 (1987) 180-183
14. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93 (1996) 9821-9826
15. Sathyanarayana U.G., Toyooka S., Padar A., Takahashi T., Brambilla E., Minna J.D., et al. Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin. Cancer Res. 9 (2003) 2665-2672
16. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst. 93 (2001) 691-699
17. Kanai Y., Ushijima S., Hui A.M., Ochiai A., Tsuda H., Sakamoto M., et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 71 (1997) 355-359
18. Maruyama R., Toyooka S., Toyooka K.O., Virmani A.K., Zochbauer-Muller S., Farinas A.J., et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8 (2002) 514-519
19. Toyooka K.O., Toyooka S., Virmani A.K., Sathyanarayana U.G., Euhus D.M., Gilcrease M., et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61 (2001) 4556-4560
20. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 63 (2003) 3735-3742
21. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22 (2003) 2021-2033
22. Evron E., Umbricht C.B., Korz D., Raman V., Loeb D.M., Niranjan B., et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61 (2001) 2782-2787
23. Padar A., Sathyanarayana U.G., Suzuki M., Maruyama R., Hsieh J.T., Frenkel E.P., et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9 (2003) 4730-4734
24. Toyooka K.O., Toyooka S., Maitra A., Feng Q., Kiviat N.C., Smith A., et al. Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am. J. Pathol. 161 (2002) 629-634
25. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Danenberg P.V., and Laird P.W. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 59 (1999) 2302-2306
26. Jeronimo C., Usadel H., Henrique R., Oliveira J., Lopes C., Nelson W.G., et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93 (2001) 1747-1752
27. Matsumura Y., and Ananthaswamy H.N. Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 195 (2004) 298-308
28. Marks R., Jolley D., Lectsas S., and Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med. J. Aust. 152 (1990) 62-66
29. Kricker A., Armstrong B.K., English D.R., and Heenan P.J. Pigmentary and cutaneous risk factors for non-melanocytic skin cancer-a case-control study. Int. J. Cancer 48 (1991) 650-662
30. Tommasi S., Denissenko M.F., and Pfeifer G.P. Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res. 57 (1997) 4727-4730
31. Jonason A.S., Kunala S., Price G.J., Restifo R.J., Spinelli H.M., Persing J.A., et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl Acad. Sci. USA 93 (1996) 14025-14029
32. Issa J.P. Age-related epigenetic changes and the immune system. Clin. Immunol. 109 (2003) 103-108
33. Matter K., and Balda M.S. Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol. 4 (2003) 225-236
34. Henning K., Berndt A., Katenkamp D., and Kosmehl H. Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast. Histopathology 34 (1999) 305-309
35. Martin K.J., Kwan C.P., Nagasaki K., Zhang X., O'Hare M.J., Kaelin C.M., et al. Down-regulation of laminin-5 in breast carcinoma cells. Mol. Med. 4 (1998) 602-613
36. Manda R., Kohno T., Niki T., Yamada T., Takenoshita S., Kuwano H., et al. Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. 275 (2000) 440-445
37. Giannelli G., and Antonaci S. Biological and clinical relevance of Laminin-5 in cancer. Clin. Exp. Metastasis 18 (2000) 439-443
38. Baker S.E., Hopkinson S.B., Fitchmun M., Andreason G.L., Frasier F., Plopper G., et al. Laminin-5 and hemidesmosomes: role of the alpha 3 chain subunit in hemidesmosome stability and assembly. J. Cell Sci. 109 Pt 10 (1996) 2509-2520
39. Zhao Y.L., Piao C.Q., and Hei T.K. Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21 (2002) 7471-7477
40. Ferguson J.W., Mikesh M.F., Wheeler E.F., and LeBaron R.G. Developmental expression patterns of Beta-ig (betaIG-H3) and its function as a cell adhesion protein. Mech. Dev. 120 (2003) 851-864